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Background: Dose-finding trials are essential to drug development as they establish recommended doses for later-phase testing.
We aim to motivate wider use of model-based designs for dose finding, such as the continual reassessment method (CRM).
Methods:We carried out a literature review of dose-finding designs and conducted a survey to identify perceived barriers to their
implementation.
Results: We describe the benefits of model-based designs (flexibility, superior operating characteristics, extended scope), their
current uptake, and existing resources. The most prominent barriers to implementation of a model-based design were lack of
suitable training, chief investigators’ preference for algorithm-based designs (e.g., 3þ 3), and limited resources for study design
before funding. We use a real-world example to illustrate how these barriers can be overcome.
Conclusions: There is overwhelming evidence for the benefits of CRM. Many leading pharmaceutical companies routinely
implement model-based designs. Our analysis identified barriers for academic statisticians and clinical academics in mirroring the
progress industry has made in trial design. Unified support from funders, regulators, and journal editors could result in more
accurate doses for later-phase testing, and increase the efficiency and success of clinical drug development. We give
recommendations for increasing the uptake of model-based designs for dose-finding trials in academia.
Dose-finding trials are essential in drug development as they establish
a recommended dose for later-phase testing. We need reliable,
efficient phase I trial designs for faster, cheaper drug development.
Phase I trials aim to find a recommended dose based on a
target/acceptable toxicity level or some other criteria and use
algorithm- or model-based designs (Braun, 2014). We focus here
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on trials determining the maximum-tolerated dose (MTD), which
is the highest dose of drug or treatment that does not cause too
many patients unacceptable side effects. Algorithm-based designs,
such as the 3þ 3 (Carter, 1987), use rules fixed during trial design
to select the MTD and allocate patients to a dose level. Dose levels
are assigned using information from patients at one dose level.
Model-based designs, such as continual reassessment (CRM)
(O’Quigley et al, 1990), allocate patients to a dose level using a
targeted toxicity rate and a statistical model describing the dose–
toxicity relationship between the dose levels. When a new patient is
registered to the trial, the model is updated using all available
information on all registered patients and the dose for the new
patient is agreed using the model-suggested dose as a guideline.
Information from every patient at every dose level is used to decide
the next dose. The model recommends the final MTD at trial
completion.
Although statisticians recommend model-based designs, most
phase I trials use algorithm-based designs (Rogatko et al, 2007; van
Brummelen et al, 2016). We need to understand why statisticians’
endorsement of model-based designs is often ignored (Jaki, 2013;
Paoletti et al, 2015) so that we can act appropriately to improve
uptake.
We summarise the benefits of model-based designs and
statisticians’ opinions of why these designs are neglected from
the literature. We survey researchers’ reasons for avoiding these
designs. We demonstrate how to overcome these barriers using a
real-world example and provide recommendations and solutions to
remove perceived barriers to using model-based designs.
MATERIALS AND METHODS
Literature review. We conducted a literature review, searching
PubMed on 13 May 2015 and Embase on 8 June 2015 for ‘3þ 3’,
‘CRM’, and general terms. Supplementary Tables A and B show
our search strategies.
Survey. We identified four themes in studies examining uptake of
adaptive designs and Bayesian methods (Chevret, 2012; Jaki, 2013;
Morgan et al, 2014; Dimairo et al, 2015a): resources, knowledge,
training, and implementation. We developed survey questions
(Supplementary Table C) to identify barriers within these themes.
We included one question for statisticians on software and another
for other respondents on statistical support.
The survey was sent to clinical academics working with
AstraZeneca, chief investigators (CIs) involved in trials reviewed
and approved by the Cancer Research UK (CRUK) New Agents
Committee (NAC), and International Clinical Trials Methodology
Conference delegates (ICTMC 2015) who registered for a dose-
finding studies workshop.
The frequency and proportion of each response was calculated
for each questionnaire item. The proportion of respondents who
considered each item a barrier was calculated by combining the
numbers who rated the item ‘always’ and ‘often’ or ‘strongly agree’
and ‘agree’.
RESULTS
Model-based approaches today. Model-based approaches have
been neglected since their introduction in the 1990s. They were
used in 1.6% of phase I trials published 1991–2006 (Rogatko et al,
2007), increasing to only 6.4% by 2012–2014 (van Brummelen
et al, 2016).
Benefits of model-based approaches. Model-based designs for
phase I trials offer flexibility, superior operating characteristics, and
scope for extension (Le Tourneau et al, 2009).
Flexibility. Model-based approaches allow complete flexibility in
defining a target dose-limiting toxicity rate and enable the MTD to
be estimated with the required degree of precision. The MTD may
therefore be defined as the highest dose with a dose-limiting
toxicity rate below the target threshold, with the threshold chosen
based on the trial patient population and prior knowledge of the
evaluated drug. Model-based designs can accommodate different
underlying dose–response curve shapes. Doses can be skipped to
accelerate escalation or de-escalation, and new dose levels can be
defined during the trial. The risk of dose-limiting toxicity events in
later treatment cycles can also be evaluated (Paoletti et al, 2015).
Superior operating characteristics. Across different dose–toxicity
curves, model-based designs select the dose with the target dose-
limiting toxicity rate more often than 3þ 3 designs (Thall and Lee,
2003; Boonstra et al, 2015) and expose fewer patients to doses with
dose-limiting toxicity rates above or below the target level during
the trial (Iasonos et al, 2008; Le Tourneau et al, 2012). The safety of
model-based designs is evaluated at the design stage using
simulation, with incorporation of overdose control where appro-
priate, and checking that decisions are sensible. Simulations have
shown that more patients are likely to be overdosed or treated at
subtherapeutic doses with 3þ 3 designs than model-based designs
(Babb et al, 1998). Model-based designs also outperform 3þ 3
designs when attribution errors for adverse events occur (Iasonos
et al, 2012). Unlike 3þ 3 designs, model-based designs can
accommodate many candidate doses without substantially
affecting the designs operating characteristics (Jaki et al, 2013).
A CRM design achieved a recommended MTD after a median
of three to four fewer patients than a 3þ 3 design (Onar et al,
2009).
Extended scope. Model-based approaches can be varied to suit a
particular intervention and trial. For example, they can incorporate
toxicity grade information (Iasonos et al, 2010; Doussau et al,
2015), combination treatments (Mandrekar et al, 2007), non-
binary end points such as biomarker, pharmacokinetic or
pharmacodynamics measures (Calvert and Plummer, 2008),
time-to-event information (Cheung and Chappell, 2000), and
multiple treatment schedules (O’Quigley and Conaway, 2011).
With so much evidence supporting model-based designs, why
do trial teams avoid them?
Possible barriers to model-based approaches. The literature
offers many opinions, and little empirical evidence, on why
model-based designs are neglected.
Algorithm-based designs such as the 3þ 3 design are the most
used oncology dose-escalation design and therefore oncologists are
exposed to and become familiar with it, and the literature offers
many practical examples (Rogatko et al, 2007). Clinicians using
3þ 3 designs often informally incorporate available data from
lower doses and use their experience of previous trials when
deciding dose allocations. Many believe that 3þ 3 designs are
flexible, practical, functioning phase I designs (Ishizuka and
Ohashi, 2001).
Model-based designs are seen as a ‘black box’ approach to dose
escalation that makes clinical interpretation of model parameters
difficult during design development. Statistical analysis is needed
after each dose cohort, which appears time consuming and
complicated. Despite strong counterevidence (O’Quigley, 1999),
many believe that model-based designs are less efficient than 3þ 3
designs in terms of time-to-complete and numbers treated above
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the MTD (Korn et al, 1994). Our experience is that clinicians also
worry that they cannot overrule a model’s dose-escalation
recommendations, and often cite 3þ 3 designs as providing safe,
conservative estimates of the MTD.
Clinicians may find model-based designs’ need for prior
information counterintuitive. As a phase I trial’s start is rife with
uncertainty, many erroneously believe that the model’s required
information can only be acquired after the trial starts. The
reliability of dose-escalation decision-making is thought to be
heavily dependent on weak prior assumptions.
Relative to algorithm-based designs, there are few published
practical examples of model-based designs; although the systematic
review of Iasonos and O’Quigley (2014) provides references of
CRM published trials from 2001 to 2013, Levy et al (2006) and
Paoletti et al (2006) are useful descriptions of trials, and Iasonos
et al (2015) guides protocol writing.
Setting up model-based designs requires time and expertise. The
statistician and CI must interact frequently, requiring access to a
statistician and time for design development (Morita et al, 2007;
Jaki, 2013; Dimairo et al, 2015b). Even when statistical advice is
available, choosing the most appropriate design for a particular
trial from the many designs on offer is challenging. Add time
constraints due to funding application deadlines, and it is
unsurprising that clinicians prefer ‘simple’, familiar methods
(Jaki, 2013; Dimairo et al, 2015b).
Survey results: perceived barriers. We surveyed clinicians,
statisticians, researchers, and trial managers to ascertain which of
the barriers identified in our literature review are currently
affecting the medical research community. We received responses
from 14 of the 62 (23%) clinical academics working with
AstraZeneca, 22 of the 45 (49%) CIs involved in trials reviewed
and approved by the CRUK NAC, and 43 of the 93 (46%)
participants registered for the ICTMC 2015 workshop giving an
overall response rate of 40% (79 out of 200).
Table 1 summarises the survey participants’ disciplines and
experience. The majority were CIs (40%) or statisticians (39%),
representing a range of experience levels. Around half had used
non-algorithm-based methods. Of the 30 participating statisticians,
53% reported access to specialised statistical software to support
design and analysis of model-based approaches. Of the 30
participating CIs, 83% reported access to statistical support to
undertake a non-rule-based design.
When designing a new trial, 53% of the respondents said they
always or often considered an alternative to algorithm-based
methods. However, 16% reported a poor experience using
alternative designs where reasons given included the reliance of
real-time data entry for CRM, which slowed down decision making
and less data available on other doses to model the efficacy curve
and undertake biomarker exploratory analysis (Supplementary
Table D).
Figure 1 shows the proportion of respondents who identified each
questionnaire item as a barrier to implementing model-based
designs. The top three barriers were lack of training to use alternative
approaches to algorithm-based designs (57%), CIs’ preference for
3þ 3 designs (53%), and limited resources for study design before
funding (50%). Many other items were also rated as barriers by a
large proportion of the respondents, such as lack of opportunities to
apply learnt skills in using alternative approaches to algorithm-based
designs and how quickly studies must be designed.
We collected free-text comments to capture other attitudes or
barriers (Supplementary Table D). The most common theme was
respondents’ experience of a model-based study that was slower or
larger than a typical 3þ 3 design. Other concerns about model-
based designs themes were: difficulties of real-time data capture,
limited data on alternative doses for pharmacodynamics, lack of
experienced statisticians, and not selecting a safe dose. Improving
uptake themes were: ‘selling’ model-based approaches to CIs and
funders, accessible software, and consensus on which model-based
approach to use.
Resources to support model-based design. Resources exist to
help trial designers overcome some of the identified barriers.
Software. UK-based non-industry statisticians have access to free
CRM software programmes, such as crmPack, dfcrm, and bcrm
(http://cran.r-project.org), R shiny apps Web Application for
simulating operating characteristics of the Bayesian CRM (Wages,
2017), and EWOC (Cedars-Sinai, 2017).
Working groups. The Medical Research Council (MRC) funds a
National Network of Hubs for Trial Methodology Research to
undertake trials methodology research. The Network’s adaptive
design working group promotes methodology and supports using
innovative designs through workshop-based advice forums,
tutorial papers, individualised support, and software development
(MRC Hubs for Trials Methodology Research, 2015). The National
Institute of Health Research Statistics Group supports translating
statistical methods into practice. Its early-phase clinical trial
initiative focuses on dose-finding studies and works with academic
researchers and industry collaborators (NIHR Statistics Group,
2016).
Table 1. Characteristics of the survey participants
Question Response N %
Are you (N¼79)
Chief investigator 31 39
Funder 1 1
Other 14 18
Statistician 30 38
Trial manager 3 4
How long have you worked with dose-finding studies? (years)
(N¼78)
0–2 10 13
3–5 12 15
6–10 12 15
11–12 14 18
20þ 5 6
New to topic 25 32
Have you ever been involved in a dose-finding study that, rather
than using 3þ3 or another rule-based design, used an
alternative? (N¼76)
No 37 49
Yes 37 49
Don’t know 2 3
Do you have access to software to support alternative
approaches to 3þ3 and other rule-based designs? Statisticians
only (N¼30)
Don’t know 6 20
No 8 27
Yes 16 53
Is appropriate statistical support available to you to undertake
alternative approaches to 3þ3 and other rule-based designs?
Chief investigators only (N¼30)
Don’t know 2 7
No 3 10
Yes 25 83
When designing a trial, how often do you consider alternatives to
3þ3 and rule-based designs (N¼77)
Always 22 29
Often 19 25
Not very often 15 19
Never 4 5
Don’t know 17 22
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Guidelines. As the statistical language used in CRM studies can
inhibit understanding, published guidelines indicate which operat-
ing characteristics to summarise to help the entire medical,
scientific, and statistical team evaluate a proposed design (Iasonos
et al, 2015). Other guidelines focus on protocols (Petroni et al,
2017).
Learning from industry. Many pharmaceutical companies have
overcome practical barriers to implementing model-based designs,
motivated by inaccurate doses from 3þ 3 trials causing failed
phase II and III studies. Academia can use these companies’
experiences (Table 2).
Practical examples. There are few published practical examples of
model-based designs (van Meter et al, 2012) or suggested design
modifications (Potter, 2002; de Lima et al, 2010; Jones et al, 2012;
Wages et al, 2015) to help overcome perceived barriers. In Box 1,
we present our experiences developing a CRM-based phase I trial
to show an example of the process.
DISCUSSION
Despite the vast literature outlining the statistical benefits of
model-based designs over algorithmic designs, model-based
methods are rarely used. In addition, in recent years there
have been advances in therapeutic strategies where the relationship
between dose and toxicity is less obvious and for which
model-based designs are necessary. The literature suggests that
time constraints, limited statistical resources, and few published
practical examples are the greatest barriers to implementation, and
that resources, knowledge, and training are the key to improving
uptake.
Lack of suitable training (74)
CI prefers 3+3 design (74)
Cls’ lack of knowledge (73)
Short turnaround for designing studies (71)
Lack of opportunities to apply what I learnt (73)
Lack of time to study what I learnt (73)
Lack of time to attend training (72)
Funders' response to increased costs (71)
Need to obtain quick, reliable for adaptation (72)
Summary_Barrier The lack of consistency in the literature (73)
Funders prefer 3+3 design (74)
Statisticians’ lack of knowlwdge (73)
Trial managers' lack of knowlwdge (73)
Regulators prefer 3+3 design (74)
Funders’ lack of knowledge (73)
Regulators’ lack of knowledge (73)
Previous poor experience (69)
Journal prefer 3+3 design (74)
0 20 40 60
Statistician prefers 3+3 design (74)
Limited resources to design study prior to funding (72)
%
Figure 1. Percentage of respondents identifying each item as a barrier to implementing model-based designs. See Supplementary Table C for all
items. CI=chief investigator.
Table 2. Pharmaceutical companies’ steps to promote model-based designsa
Company Model-based designs Key activities
AstraZeneca All early oncology dose-escalation trials since 2014 Education programme
Routine trial simulation software
Standard method for prior toxicity–response curves
All possible dose–response scenarios prepared for dose-
escalation meetings
Roche Pharmaceutical
Research and Early
Development
Standard approach for oncology dose-escalation studies Developed R software package, crmPack, for simulating,
visualising, and running CRM studies
Joint scientific forums between statistical and medical
colleagues
Examples of deployed designs
Boehringer Ingelheim Standard approach for dose-finding (two-parameter Bayesian
logistic regression model (Neuenschwander et al, 2008) with
overdose control)
Expert statistics group provides support
Training for statisticians and non-statisticians
Template text for clinical trial protocols
Template R and SAS (SAS Institute Inc., Cary, NC, USA)
programmes for protocols, steering committee meetings, and
clinical trial reports
Abbreviation: CRM¼ continual reassessment method.
aInformation provided by authors of this paper.
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We surveyed clinicians, statisticians, and trialists interested in
dose-finding trials on their opinions of what stops trial teams from
using model-based designs. We approached 200 people; 40%
responded. As we targeted a convenient sample of researchers
involved or interested in phase I methodology, our results may not
be representative of the dose-finding research community. Those
acquainted with model-based designs may have been more likely to
respond, as 83% of the clinical respondents reported access to
statistical support to implement a model-based approach, and 53%
of the statistician respondents reported access to suitable software.
Although the sample may not be a cross-section of the dose-
finding community, the opinions of experienced researchers
familiar with model-based methods provide valuable insights.
Our results agree with previous surveys of similar scope but wider
focus (Jaki, 2013; Dimairo et al, 2015b).
We did not identify one obvious barrier. Many barriers were
considered important by a large proportion of respondents,
including clinician and statistician lack of knowledge; clinician,
statistician, and funder preferences; lack of training and time for
study design before funding; and funder responses to increased
costs. A step change in practice will require a multifold approach
targeting funders, clinicians, and statisticians.
We discuss the identified barriers to uptake, the progress thus
far, and suggestions for facilitating change, referring to our real-
world example in Box 1 (see summary in Table 4).
Expectations. Many of our respondents avoided model-based
designs as previous attempts had resulted in larger or slower trials
than expected. Model-based designs do not necessarily mean
smaller phase I trials. Instead, these designs more accurately
identify the correct dose for future studies, reducing dose re-
evaluations and improving efficiency and success in the more
expensive later stages of drug development.
Training. Our respondents rated lack of training as the greatest
barrier to using model-based designs. The MRC’s adaptive design
Box 1. Planning and executing a phase I trial with a
Bayesian design: real-world example
Objective: Perform an open-label single-compound dose-escalation trial to
find a new compound’s MTD.
The team agreed to consider a model-based approach to explore doses
ranging from 0.2 to 120mg. The statisticians explained the proposed design
to the clinicians. They emphasised the advantages of a model-based
design over a 3þ 3 design: flexibility in choosing the next dose and in
cohort sizes, and superior operating characteristics. As reliable results
were important, the medical trial team agreed to use a Bayesian model-
based approach.
The model-based design needed a prior probability distribution capturing
the clinicians’ prior beliefs about toxicity at different doses and their
uncertainty in these beliefs. The statisticians and clinicians discussed
their expectations of the new compound’s toxicity. As no clinical data
were available, the clinicians estimated the toxicity rates at specific
doses for best-case, worst-case, and expected scenarios. As these
estimates were based on scant information, they were used to form a
minimally informative mixture prior; the information had a small effect on
the trial.
The statisticians calculated the prior effective sample size to show the
clinicians that the prior’s information would not overrule information
gathered in the trial. The study design included safety constraints, such as
no dose skipping and not recommending doses when the probability of a
dose-limiting toxicity was above a threshold.
Hypothetical data scenarios were chosen to reflect potential on-study
constellations and the model’s recommended escalation decisions were
considered. Complete trials were simulated to demonstrate that the model
gave reasonable MTD recommendations. As template programmes were
used, simulating 3000 trials took just 4–5 h.
To show the team what they could expect in steering committee
meetings, Figure 2 and Table 3 were created before the trial started. They
represent an example output for a dose-escalation meeting after one
hypothetical patient has taken 5mg without toxicity. The Bayesian model
considered doses up to 10mg safe as they had low probabilities of
overtoxicity (Figure 2, top). It classified the dose level most likely to reach
the target toxicity range 16–32%, 40mg, as too risky for overtoxicity. It
recommended testing 10mg next.
The statisticians explained that the model gives recommendations
that the steering committee members can overrule, not binding rules. The
statistical report will clearly describe the dose-escalation decisions that
were made in the trial.
Table 3. Toxicity interval probabilities for all prespecified
dose levels after one patient has been treated with 5mg
Probability of toxicity rate in
Dose
(mg)
(0–0.16)
Undertoxicity
(0.16–0.33)
Target
toxicity
(0.33–1)
Overtoxicity
Mean
toxicity rate
0.2 0.889 0.065 0.046 0.056
0.5 0.860 0.075 0.065 0.071
1 0.828 0.089 0.083 0.086
2.5 0.770 0.115 0.115 0.112
5 0.717 0.128 0.155 0.140
10 0.649 0.144 0.207 0.177
20 0.559 0.163 0.278 0.228
40 0.439 0.186 0.374 0.300
80 0.301 0.179 0.520 0.403
120 0.231 0.167 0.601 0.473
Numbers in bold indicate safe, and those in italics indicate unsafe.
Interval probabilities
1
0.5
0.5
Pr
ob
ab
ilit
y
0
0
0.5
0
Dose (mg) 0.2
0/1
0.5 2.5 5 10 20 40 80 1201
Data
Figure 2. Toxicity interval probabilities for all prespecified dose levels
after one patient has been treated with 5mg, showing the
probabilities for (top) over-, (middle) target, and (bottom)
undertoxicity. With green indicating safe doses and red indicating
unsafe doses, this shows the current dose decision can be based solely
on overtoxicity since only the overtoxicity graph has red doses. We wish
to increase the dose if we can; the current patient took 5 mg, but 10 mg
would also be safe; thus, the model proposes 10 mg for the next
patient.
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working group (MRC Hubs for Trials Methodology Research,
2015) promotes the use of model-based design through publica-
tions, workshops, expert advice forums, and individualised support
for statisticians. There are some explanatory papers (Garrett-
Mayer, 2006). However, little practical training exists on designing
and implementing CRM-based designs throughout a trial’s life.
More publications on the practicalities are required.
Lack of time. Two frequently reported barriers were how quickly
studies are designed and lack of time to study and apply methods.
Promoting earlier, frequent discussion of trial ideas between
clinicians and statisticians may mitigate these time constraints. Our
real-world example shows that ongoing discussion between
statisticians and clinicians helps ensure that the final design
reflects clinical opinion.
Design evaluation. Our survey highlighted lack of resources for
evaluating trial designs as a barrier. The example in Box 1 shows
that software templates can speed up design evaluation. Sufficient
software training and support during grant development would be
very valuable.
Regulators. Over 20% of our respondents believed that regulators
prefer 3þ 3 designs and a similar percentage felt regulators lack
knowledge of other designs. However, UK regulators do endorse
other trial designs, and the European regulatory guidance on first-
in-man trials (Committee for Medicinal Products for Human Use,
2007) does not dictate a design (ICH E4, 1994; Hemmings, 2006;
European Medicines Agency, 2014; Europeans Medicines Agency,
2015). Experiences from pharmaceutical companies show that
model-based designs are readily accepted by health authorities and
ethics boards.
A model-based phase I trial design must be described and
justified in a clinical trial authorisation application like any other
design choice. Regulators evaluate the appropriateness of the
chosen method in the application’s context. We encourage
regulators to make their position clear to clinicians and
statisticians.
Funders. Funders drive the academic clinical research agenda by
setting strategic health priorities and commissioning research
projects. They influence the direction and quality of research, as
researchers aim to deliver what funders demand. Funders can play
a pivotal role in encouraging better statistical methods in the
design and analysis of dose-finding studies by setting strategic
objectives, implementing rigorous statistical peer review, and
integrating statistical expertise into their processes. We encourage
funding bodies and ethics committees to question the use of
algorithm-based designs, conduct statistical reviews of all phase I
trial applications, and embrace model-based studies.
Ignorance of the benefits of model-based designs and dis-
advantages of algorithm-based designs is blocking wider imple-
mentation of more efficient phase I trial designs. Educating
funding bodies, ethics committees, and regulatory agencies via
tailored training sessions will enable more scientific appraisal of
phase I trial designs. This will provide a greater return on
investment: studies will produce more reliable results, increasing
the likelihood of successful drug development. We can extend these
principles to publications. Journal editors and reviewers should
question study designs and how they affect the reliability of dose
recommendations for future studies.
CONCLUSION
By encouraging earlier clinical and statistical discussion, high-
lighting available training resources and practical examples, and
calling for education for funders and other review committees, we
hope to help overcome the barriers to model-based designs
identified here. Implementing model-based designs will generate
more accurate dose recommendations for later-stage testing and
increase the efficiency and likelihood of successful drug
development.
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Table 4. Summary of recommendations to increase the uptake of model-based designs in academia
Item Recommendations
Misconceptions CI’s disillusioned with the idea that model-
based ideas are more efficient
Address perceptions of ‘efficiency’ for model-based designs. Communicate that this means
more often accurately identifying the correct dose rather than meaning an individual study will
be shorter in duration or have a lower sample size
Perception that regulators prefer 3þ3 Communicate that UK regulators do endorse other trial designs and European regulatory
guidance does not dictate use of a particular trial design
Training Supporting uptake of model-based
designs by statisticians and CIs
While training courses for utilising bespoke expensive software exist, training courses providing
a broad academic introduction to the field and utilising free or inexpensive software need to be
developed
More publications on the practicalities of setting up and running model-based trials
Appraisal of studies by funding bodies and
ethics committees
Develop tailored training sessions for key partners to support a thorough scientific appraisal of
proposed designs of phase I trials
Model-based dose-finding experienced
statisticians contact
Develop a forum for contacting experienced statisticians
Design and
evaluation
Lack of time to design and evaluate a
model-based approach
Promote the need for early discussions between CI and statisticians to allow time to develop
and evaluate
Develop software and protocol templates
Funding Question routine use of 3þ 3 designs Encourage funders to question the use of algorithm-based designs and embrace the idea of
more efficient model-based studies
Lack of statistical review for applications Include statistical representation on funding board
Abbreviation: CI¼ chief investigator.
Embracing model-based designs for dose finding BRITISH JOURNAL OF CANCER
www.bjcancer.com |DOI:10.1038/bjc.2017.186 337
CONFLICT OF INTEREST
BG-M is an employee of Boehringer Ingelheim Pharma GmbH &
Co. KG, CH is an employee of Roche Pharmaceuticals and JM is an
employee of AstraZeneca. The other authors declare no other
conflict of interest.
REFERENCES
Babb J, Rogatko A, Zacks S (1998) Cancer phase I clinical trials: efficient dose
escalation with overdose control. Stat Med 17(10): 1103–1120.
Boonstra PS, Shen J, Taylor JM, Braun TM, Griffith KA, Daignault S,
Kalemkerian GP, Lawrence TS, Schipper MJ (2015) A statistical evaluation
of dose expansion cohorts in phase I clinical trials. J Natl Cancer Inst
107(3): pii: dju429.
Braun TM (2014) The current design of oncology phase I clinical trials:
progressing from algorithms to statistical models. Chin Clin Oncol 3(1): 2.
Calvert AH, Plummer R (2008) The development of phase I cancer trial
methodologies: the use of pharmacokinetic and pharmacodynamic end
points sets the scene for phase 0 cancer clinical trials. Clin Cancer Res
14(12): 3664–3669.
Carter SK (1987) The phase I study. In: Hellmann K, Carter SK (eds).
Fundamentals of Cancer Chemotherapy. McGraw-Hill: New York, NY,
USA, pp xv, p 527.
Cedars-Sinai (2017) Web-EWOC: Interactive web tool for Designing and
Conducting Dose Finding Trials in Cancer, Vol. 2017. Available at: https://
biostatistics.csmc.edu/ewoc/ewocWeb.php (last accessed 26 April 2017).
Cheung YK, Chappell R (2000) Sequential designs for phase I clinical trials
with late-onset toxicities. Biometrics 56(4): 1177–1182.
Chevret S (2012) Bayesian adaptive clinical trials: a dream for statisticians
only? Stat Med 31(11–12): 1002–1013.
Committee for Medicinal Products for Human Use (2007) Guideline on
strategies to identify and mitigate risks for first-in-human clinical trials
with investigational medicinal products. European Medicines Agency:
London, UK. Doc. ref.emea/chmp/swp/28367/07. Available at: http://
www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/
2009/09/WC500002988.pdf (last accessed 17 January 2017).
de Lima M, Giralt S, Thall PF, Silva LD, Jones RB, Komanduri K, Braun TM,
Nguyen HQ, Champlin R, Garcia-Manero G (2010) Maintenance therapy
with low-dose azacitidine after allogeneic hematopoietic stem cell
transplantation for recurrent acute myelogenous leukemia or
myelodysplastic syndrome. Cancer 116(23): 5420–5431.
Dimairo M, Boote J, Julious SA, Nicholl JP, Todd S (2015a) Missing steps in a
staircase: a qualitative study of the perspectives of key stakeholders on the
use of adaptive designs in confirmatory trials. Trials 16: 430.
Dimairo M, Julious SA, Todd S, Nicholl JP, Boote J (2015b) Cross-sector
surveys assessing perceptions of key stakeholders towards barriers,
concerns and facilitators to the appropriate use of adaptive designs in
confirmatory trials. Trials 16: 585.
Doussau A, Thiebaut R, Geoerger B, Schoffski P, Floquet A, Le Deley MC,
Mathoulin-Pelissier S, Rizzo E, Fumoleau P, Le Tourneau C, Paoletti X
(2015) A new approach to integrate toxicity grade and repeated treatment
cycles in the analysis and reporting of phase I dose-finding trials. Ann
Oncol 26(2): 422–428.
European Medicines Agency (2014) Qualification Opinion of MCP-Mod as
an Efficient Statistical Methodology for Model-Based Design and Analysis
of Phase II Dose Finding Studies Under Model Uncertainty, Vol. 2014.
European Medicines Agency: London, UK. Doc ref EMA/CHMP/SAWP/
757052/2013. Available at: http://www.ema.europa.eu/docs/en_GB/
document_library/Regulatory_and_procedural_guideline/2014/02/
WC500161027.pdf (last accessed 17 January 2017).
Europeans Medicines Agency (2015) Report from Dose Finding Workshop,
Vol. 2015. European Medicines Agency: London, UK. Doc ref EMA/
117491/2015. Available at: http://www.ema.europa.eu/docs/en_GB/
document_library/Report/2015/04/WC500185864.pdf (last accessed 16
January 2017).
Garrett-Mayer E (2006) The continual reassessment method for dose-finding
studies: a tutorial. Clin Trials 3(1): 57–71.
Hemmings R (2006) Philosophy and methodology of dose-finding – a
regulatory perspective. In: Chevret S (ed). Statistical Methods for Dose-
Finding Experiments. Wiley: Chichester, UK.
Iasonos A, Gonen M, Bosl GJ (2015) Scientific review of phase I protocols
with novel dose-escalation designs: how much information is needed? J
Clin Oncol 33(19): 2221–2225.
Iasonos A, Gounder M, Spriggs DR, Gerecitano JF, Hyman DM, Zohar S,
O’Quigley J (2012) The impact of non-drug-related toxicities on the
estimation of the maximum tolerated dose in phase I trials. Clin Cancer
Res 18(19): 5179–5187.
Iasonos A, O’Quigley J (2014) Adaptive dose-finding studies: a review of
model-guided phase I clinical trials. J Clin Oncol 32(23): 2505–2511.
Iasonos A, Wilton AS, Riedel ER, Seshan VE, Spriggs DR (2008) A
comprehensive comparison of the continual reassessment method to the
standard 3þ 3 dose escalation scheme in phase I dose-finding studies. Clin
Trials 5(5): 465–477.
Iasonos A, Zohar S, O’Quigley J (2010) Two-stage continual reassessment
method that determines dose escalation based on individual toxicity
grades. Clin Trials 7: 496.
ICH E4 (1994) Dose–Response Information to Support Drug Registration,
Vol. 1994. The International Council for Harmonisation of Technical
Requirements for Pharmaceuticals for Human Use (ICH): Geneva,
Switzerland. Available at: http://www.ich.org/fileadmin/Public_Web_Site/
ICH_Products/Guidelines/Efficacy/E4/Step4/E4_Guideline.pdf (last
accessed 16 January 2017).
Ishizuka N, Ohashi Y (2001) The continual reassessment method and its
applications: a Bayesian methodology for phase I cancer clinical trials. Stat
Med 20(17–18): 2661–2681.
Jaki T (2013) Uptake of novel statistical methods for early-phase clinical
studies in the UK public sector. Clin Trials 10(2): 344–346.
Jaki T, Clive S, Weir CJ (2013) Principles of dose finding studies in cancer:
a comparison of trial designs. Cancer Chemother Pharmacol 71(5): 1107–1114.
Jones DR, Moskaluk CA, Gillenwater HH, Petroni GR, Burks SG, Philips J,
Rehm PK, Olazagasti J, Kozower BD, Bao YD (2012) Phase I trial of
induction histone deacetylase and proteasome inhibition followed by
surgery in non-small-cell lung cancer. J Thorac Oncol 7(11): 1683–1690.
Korn EL, Midthune D, Chen TT, Rubinstein LV, Christian MC, Simon RM
(1994) A comparison of 2 phase-I trial designs. Stat Med 13(18):
1799–1806.
Le Tourneau C, Gan HK, Razak AR, Paoletti X (2012) Efficiency of new dose
escalation designs in dose-finding phase I trials of molecularly targeted
agents. PLoS ONE 7(12): e51039.
Le Tourneau C, Lee JJ, Siu LL (2009) Dose escalation methods in phase I
cancer clinical trials. J Natl Cancer Inst 101(10): 708–720.
Levy V, Zohar S, Bardin C, Vekhoff A, Chaoui D, Rio B, Legrand O, Sentenac
S, Rousselot P, Raffoux E, Chast F, Chevret S, Marie JP (2006) A phase I
dose-finding and pharmacokinetic study of subcutaneous semisynthetic
homoharringtonine (ssHHT) in patients with advanced acute myeloid
leukaemia. Br J Cancer 95(3): 253–259.
Mandrekar SJ, Cui Y, Sargent DJ (2007) An adaptive phase I design for
identifying a biologically optimal dose for dual agent drug combinations.
Stat Med 26(11): 2317–2330.
Morgan CC, Huyck S, Jenkins M, Chen L, Bedding A, Coffey CS, Gaydos B,
Wathen JK (2014) Adaptive design: results of 2012 survey on perception
and use. Ther Innov Regul Sci 48(4): 473–481.
Morita S, Toi M, Saji S, Iwata H, Ohno S, Ito Y, Kobayashi T, Hozumi Y,
Sakamoto J (2007) Practical application of the continual reassessment
method to a phase I dose-finding trial in advanced breast cancer. Drug Inf
J 41(6): 691–700.
MRC Hubs for Trials Methodology Research (2015) Network Hubs: Adaptive
Designs, Vol. 2016. Medical Research Council: London, UK. Available at:
http://www.methodologyhubs.mrc.ac.uk/research/working-groups/
adaptive-designs/ (last accessed 8 December 2016).
Neuenschwander B, Branson M, Gsponer T (2008) Critical aspects of the
Bayesian approach to phase I cancer trials. Stat Med 27(13): 2420–2439.
NIHR Statistics Group (2016) Research: Early Phase Trials, Vol. 2016. King’s
College London: London, UK. Available at: http://statistics-
group.nihr.ac.uk/research/early-phase-clinical-trials (last accessed
8 December 2016).
O’Quigley J (1999) Another look at two phase I clinical trial designs. Stat Med
18(20): 2683–2690.
O’Quigley J, Conaway M (2011) Extended model-based designs for more
complex dose-finding studies. Stat Med 30(17): 2062–2069.
O’Quigley J, Pepe M, Fisher L (1990) Continual reassessment method: a
practical design for phase 1 clinical trials in cancer. Biometrics 46(1):
33–48.
BRITISH JOURNAL OF CANCER Embracing model-based designs for dose finding
338 www.bjcancer.com |DOI:10.1038/bjc.2017.186
Onar A, Kocak M, Boyett JM (2009) Continual reassessment method vs.
traditional empirically based design: modifications motivated by phase I
trials in pediatric oncology by the Pediatric Brain Tumor Consortium.
J Biopharm Stat 19(3): 437–455.
Paoletti X, Baron B, Schoffski P, Fumoleau P, Lacombe D, Marreaud S,
Sylvester R (2006) Using the continual reassessment method: lessons
learned from an EORTC phase I dose finding study. Eur J Cancer 42(10):
1362–1368.
Paoletti X, Ezzalfani M, Le Tourneau C (2015) Statistical controversies in
clinical research: requiem for the 3þ 3 design for phase I trials. Ann Oncol
26(9): 1808–1812.
Petroni GR, Wages NA, Paux G, Dubois F (2017) Implementation of adaptive
methods in early-phase clinical trials. Stat Med 36(2): 215–224.
Potter DM (2002) Adaptive dose finding for phase I clinical trials of drugs
used for chemotherapy of cancer. Stat Med 21(13): 1805–1823.
Rogatko A, Schoeneck D, Jonas W, Tighiouart M, Khuri FR, Porter A (2007)
Translation of innovative designs into phase I trials. J Clin Oncol 25(31):
4982–4986.
Thall PF, Lee SJ (2003) Practical model-based dose-finding in phase I
clinical trials: methods based on toxicity. Int J Gynecol Cancer 13(3):
251–261.
van Brummelen EMJ, Huitema ADR, van Werkhoven E, Beijnen JH,
Schellens JHM (2016) The performance of model-based versus rule-
based phase I clinical trials in oncology. J Pharmacokinet Pharmacodyn 43:
235–242.
van Meter E, Slone S, Weiss H, Reynolds J, Hayslip J (2012) Implementation
of likelihood-based continual reassessment method designs in dose finding
trials. Clin Trials 9: 550.
Wages NA (2017)Web Application for Simulating Operating Characteristics of
the Bayesian CRM: Bayesian Continual Reassessment Method for Phase I
Clinical Trials. Available at: https://uvatrapps.shinyapps.io/crmb/
(last accessed 27 April 2017).
Wages NA, Read PW, Petroni GR (2015) A phase I/II adaptive design for
heterogeneous groups with application to a stereotactic body radiation
therapy trial. Pharm Stat 14(4): 302–310.
This work is licensed under the Creative Commons
Attribution 4.0 International License. To view a copy
of this license, visit http://creativecommons.org/licenses/by/4.0/
r The Author(s) named above 2017
Supplementary Information accompanies this paper on British Journal of Cancer website (http://www.nature.com/bjc)
Embracing model-based designs for dose finding BRITISH JOURNAL OF CANCER
www.bjcancer.com |DOI:10.1038/bjc.2017.186 339
